This article first appeared on GuruFocus .
-
Revenue:INR384 crore, up 20% year-on-year.
-
EBITDA:INR63.5 crore, up 10% year-on-year.
-
Profit After Tax (PAT):INR16.3 crore, up 55% year-on-year.
-
Base Business Revenue:INR307 crore, up 24% year-on-year.
-
Gross Margin:INR158 crore, up 10% year-on-year.
-
Base Business EBITDA:INR72 crore, up 8% year-on-year.
-
Ibuprofen Business EBITDA Margin:Negative 12%.
-
EBITDA Margin:17%, with an improvement of 80 basis points quarter-on-quarter.
-
Net Debt Reduction:Reduced by INR135 crore during the quarter.
-
Net Debt:INR479 crore as of June 30, with a net debt-to-EBITDA multiple of 1.9x.
-
Warning! GuruFocus has detected 3 Warning Sign with BOM:541540.
-
Is BOM:541540 fairly valued? Test your thesis with our free DCF calculator.
Release Date: July 23, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Solara Active Pharma Sciences Ltd ( BOM:541540 ) reported a 20% year-on-year increase in overall revenues, reaching INR384 crore.
-
The company achieved its highest EBITDA and PAT in the last 18 quarters, with EBITDA up 10% year-on-year and PAT up 55% year-on-year.
-
The base business revenues grew by 24% year-on-year, demonstrating strong momentum and operational execution.
-
Net debt was reduced by INR135 crore during the quarter, reflecting a 22% reduction, and the company aims to further reduce it by the end of March '27.
-
The company is focusing on expanding existing business, seeding new businesses, and optimizing working capital to drive sustainable profitability growth.
Negative Points
-
The commodity Ibuprofen business continues to face profitability challenges, with an EBITDA margin of negative 12%.
-
The ongoing geopolitical developments in West Asia have led to higher raw material prices, impacting cost pressures.
-
Gross margins were marginally lower on a quarter-on-quarter basis due to raw material pricing and supply challenges.
-
The company faces challenges in passing on increased raw material costs to customers, impacting profitability.
-
The strategic review of the Ibuprofen business is still ongoing, with no definitive resolution yet, creating uncertainty.
Q & A Highlights
Q: As you look ahead over the next 12 to 18 months, what are the top operational priorities for Solara's turnaround? A: Sandeep Rao, Managing Director & CEO, highlighted three priorities: expanding existing business and seeding new ones, driving operational efficiency without building new facilities, and optimizing working capital to generate free cash for business funding.
Q: Are you still comfortable with the timeline for the Ibuprofen strategic review? A: Sandeep Rao confirmed that they are working towards an optimal solution and expect to address the issue by the end of H1 FY27.
Q: What is the biggest driver of profitability improvement over the next two quarters? A: Sarat Kumar, CFO, stated that growth should come from business expansion and gross margin expansion driven by incremental volumes, rather than operating leverage.
Q: Why have gross margins been fluctuating over a wide range? A: Sarat Kumar explained that the fluctuations are due to incremental cost pass-throughs and changes in product mix. Adjusting for these, the gross margin profile remains consistent with historical levels.
Q: What are the potential risks that could derail the turnaround over the next 12 to 24 months? A: Sandeep Rao identified the West Asia crisis as a major risk, affecting raw material availability and prices. The company is managing these challenges but acknowledges the macroeconomic environment's unpredictability.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
